@essapharma.com
Developing novel therapies for the treatment of prostate cancer.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
PNG
About
Description
ESSA Pharma is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for the treatment of prostate cancer. Their primary focus is on disrupting the androgen receptor signaling pathway, which is the main driver of prostate cancer growth. Their lead clinical candidate, EPI-7386, represents a groundbreaking approach to targeting this pathway and has shown promising results.
Prostate cancer is the second most common cancer in men in the United States. Current treatment options typically involve androgen deprivation therapy and antiandrogen therapies, which target the ligand binding domain of the androgen receptor. However, ESSA Pharma is taking a different approach by targeting the N-terminal domain of the androgen receptor, an area not targeted by other therapies.
ESSA Pharma is actively involved in clinical trials for their therapies, with a Phase 1 trial of EPI-7386 in patients with castration-resistant prostate cancer, as well as a Phase 1/2 trial of EPI-7386 in combination with enzalutamide for patients with metastatic CRPC. With a strong scientific focus and a commitment to advancing prostate cancer treatment, ESSA Pharma is at the forefront of developing the next generation of therapies for this devastating disease
Company Type
Public Company
Company Size
11-50
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories